DelistingAug 21, 2026, 05:11 PM
Pasithea Therapeutics Gets Nasdaq Extension to Avoid Delisting
AI Summary
Pasithea Therapeutics Corp. has been granted an additional 180-day extension by Nasdaq to meet the minimum bid price requirement of $1.00 per share. The company initially received a non-compliance notice on February 20, 2026, and had until August 19, 2026, to comply. The new deadline is February 16, 2027. Pasithea is exploring strategies, such as a reverse stock split, to regain compliance. Failure to do so could lead to the delisting of its common stock from Nasdaq.
Key Highlights
- Pasithea Therapeutics received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, now due February 16, 2027.
- The company was previously notified on February 20, 2026, of non-compliance with the $1.00 minimum bid price rule.
- Pasithea Therapeutics is considering options to regain compliance, including a potential reverse stock split.
- Failure to regain compliance by February 16, 2027, could result in the delisting of the company's common stock from Nasdaq.
Price Impact
More from KTTA